3篇
您的检索式：作者名="Runzhen Zhao"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Fibrinolytic niche is required for alveolar type 2 cell-mediated alveologenesis via a uPA-A6-CD44^(+)-ENaC signal cascade显示文摘Dear Editor,COVID-19,SARS,and MERS are featured by suppressed lungfibrinolysis.The primary objective of this study was to decipherthe role of the fibrinolytic niche in the progenitor alveolar type 2(AT2)cell-mediated re-alveolarization.The expression of Piau inAT2 cells has been confirmed at the mRNA,protein,and functionallevel across species.We employed influenza-infected&Plau^(-/-)mice,3D organoids,and polarized monolayers to track AT2 fate.We found a marked reduction in total AT2 cells and CD44^(+)subpopulation when the fibrinolytic niche was disrupted. | Gibran Ali Mo Zhang Runzhen Zhao Krishan GJain Jianjun Chang Satoshi Komatsu Beiyun Zhou Jiurong Liang Michael AMatthay Hong-Long Ji | 2021 | Signal Transduction and Targeted Therapy2021，6，3： | 0 |
| 2 | Long-term Management of Patients with Myocardial Infarction:An Updated Review显示文摘The outcomes of patients with myocardial infarction(MI)have substantially improved given the rapid progress that has occurred in revascularization techniques and secondary prevention,and the majority of MI patients subsequently enter a chronic stable phase.Therefore,the long-term management of patients with MI has become a core issue in daily clinical practice for cardiologists.The long-term incidence of adverse events can be further reduced using newly developed medications and therapies ranging from lipid-lowering agents(eg,proprotein convertase subtilisin/kexin type 9 inhibitors)to anti-thrombotic treatments(eg,shortened dual anti-platelet therapy).However,a considerable number of patients still experience adverse events,as some residual risk can remain despite intensive secondary prevention,such as continuously elevated cholesterol levels,chronic cardiovascular inflammation,and rapid atherosclerosis progression due to increased plaque instability.Therefore,the present review sought to summarize and discuss recent advances in several key aspects regarding the long-term management of MI patients,with the expectation of clarifying the available treatment strategies for various clinical scenarios,examining the gaps between trial evidence and clinical practice,and providing possible directions for future research. | Runzhen Chen Hanjun Zhao Hongbing Yan | 2022 | Cardiology Discovery2022，2，4： | 0 |
| 3 | Fibrinolytic therapy for COVID-19:a review of case series显示文摘Thromboembolism is the leading cause of mortality in COVID-19 patients.Thrombi,including pulmonary embolism(PE)and deep vein thrombosis(DVT),range from minor sequelae to fatal complications of SARS-CoV-2 infection[1].Individuals with pre-existing conditions are more likely to develop thrombi and have poor outcomes[2].The guidelines from professional societies for the use of fibrinolytic therapy(FT)in COVID-19 are inconsistent[3]. | Hong-Long Ji Yuling Dai Runzhen Zhao | 2022 | Acta Pharmacologica Sinica2022，43，8： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员